Does d-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Rodrigues, Helga ^a   Figueira, Ivan ^a   Lopes, Alessandra ^a   Gonca̧lves, Raquel ^a   Mendlowicz, Mauro Vitor ^b   Coutinho, Evandro Silva Freire ^c   Ventura, Paula ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; PLACEBO; ANTIMETABOLITE;

ACROPHOBIA; AGORAPHOBIA; ANXIETY DISORDER; BEHAVIOR THERAPY; COGNITIVE THERAPY; DRUG EFFICACY; EXPOSURE AND RESPONSE PREVENTION; EXPOSURE THERAPY; FEAR; HUMAN; LOW DRUG DOSE; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCHOEDUCATION; REINFORCEMENT; REVIEW; SNAKE PHOBIA; SOCIAL PHOBIA; SYSTEMATIC REVIEW; VIRTUAL REALITY EXPOSURE THERAPY; ANXIETY DISORDERS; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MEDLINE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIMETABOLITES; ANXIETY DISORDERS; CYCLOSERINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903759980     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093519     Document Type: Review

References (71)

1. Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, et al. (1988) One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiat 45 (11): 977-986. (Pubitemid 18261759)
2. Lepine JP (2002) The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiat 63 (14): 4-8.
3. Mendlowicz MV, Stein MB (2000) Quality of life in individuals with anxiety disorders. Am J Psychiatry 157 (5): 669-682. (Pubitemid 30249642)
4. Kessler RC, Greenberg PE (2002) The economic burden of anxiety and stress disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C (2002) Lippincott Williams and Wilkins (Eds.), Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA, 981-992.
5. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, et al. (1999) The economic burden of anxiety disorders in the 1990s. J Clin Psychiat 60 (7): 427-435. (Pubitemid 29369796)
6. World Health Organization (2001) The World Health Report 2001: Mental Health - New Understanding, New Hope. Geneva, World Health Organization.
7. Bystritsky A (2006) Treatment-resistant anxiety disorders. Mol Psychiatr 11: 805-814.
8. Foa EB, Franklin ME, Moser J (2002) Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiat 52 (10): 987-997. (Pubitemid 35356356)
9. Barlow DH, Gorman JM, Shear MK, Woods SW (2000) Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 283 (19): 2529-2536. (Pubitemid 30324195)
10. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, et al (2003) Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 71 (6): 1058-1067. (Pubitemid 37448896)
11. Foa EB, Liebowitz MR, Kosak MJ, Davies S, Campeas R, et al (2005) Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiat 162: 151-161. (Pubitemid 40095685)
12. Hofmann SG, Smits JAJ (2008) Cognitive-behavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. J Clin Psychiat 69 (4): 621-632. (Pubitemid 351792338)
13. Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, et al. (2008) Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 25: 467-476. (Pubitemid 351898386)
14. Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19 (2): 179-200.
15. Lurie I, Levine SZM (2010) Meta-Analysis of Dropout Rates in SSRIs Versus Placebo in Randomized Clinical Trials of PTSD. J Nerv Ment Dis 198 (2): 116-124.
16. Schottenbauer MA, Glass DB, Arnkoff DB, Tendick AV, Gray SH (2008) Nonresponse and Dropout Rates in Outcome Studies on PTSD: Review and Methodological Considerations. Psychiatry 71 (2): 134-168.
17. Hembree EA, Foa EB, Dorfan MN, Street GP, Kowalski J, et al. (2003) Do Patients Drop Out Prematurely From Exposure Therapy for PTSD? J Trauma Stress 16 (6): 555-562. (Pubitemid 37541825)
18. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, et al. (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiat 56 (1): 21-27. (Pubitemid 29055046)
19. Tsai GE, Falk WE, Gunther J, Coyle JT (1999) Improved cognition in Alzheimer's disease with short-term d-cycloserine treatment. Am J Psychiat 156 (3): 467-469. (Pubitemid 29124172)
20. Sheering CM, Seim RW, Spates CR (2012) A new appraisal of combined treatments for PTSD in the era of psychotherapy adjunctive medications. J Contemp Psychother 42: 69-76.
21. Walker DL, Ressler KJ, Lu KT, Davis M (2002) Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of D-Cycloserine as Assessed with Fear-Potentiated Startle in Rats. J Neurosci 22 (6): 2343-2351. (Pubitemid 35386533)
22. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
23. th edition. Washington, DC: American Psychiatric Association.
24. Higgins JPT, Altman DG (2008) Assessing risk of bias in included studies. In: Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell: 188-241.
25. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a metaanalysis. Statistics in Medicine 21: 1539-1558.
26. Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, et al. (2010) A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiat 68 (11): 1073-1076.
27. Scahill L, Riddle MA, McSwiggan-Hardin M, Ort SI, King RA, et al. (1997) Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiat 36 (6): 844-852. (Pubitemid 27250450)
28. Guy W (1970) Clinical global impression. Manual for the ECDEU assessment battery.
29. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, et al. (2007) D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiat 62 (8): 835-838. (Pubitemid 47488217)
30. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, et al. (1989) The Yale-Brown Obsessive Compulsive Scale-I: development, use, and reliability. Arch Gen Psychiatry 46: 1006-1011. (Pubitemid 19278229)
31. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, et al. (2008) Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiat 165 (3): 335-341. (Pubitemid 351704489)
32. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, et al. (2007) D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharm 22 (4): 230-237. (Pubitemid 46801947)
33. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, et al. (2004) Cognitive Enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiat 61 (11): 1136-1144. (Pubitemid 39463415)
34. Cohen D (1977) Comparison of self-report and overt-behavioral procedures for assessing acrophobia. Behav Ther 8: 17-23.
35. Tart CD, Handelsman PR, DeBoer LB, Rosenfield D, Pollack MH, et al. (2012) Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiat Res 47 (2): 168-174.
36. Nave AM, Tolin DF, Stevens MC (2012) Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. J Clin Psychiatry 73 (9): 1179-1186.
37. Klorman R, Weerts TC, Hastings JE, Melamed BG, Lang PJ (1974) Psychometric description of some specific fear questionnaires. Behav Ther 5(3): 401-409.
38. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, et al. (2010) Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiat 67 (4): 365-370.
39. Shear MK (1997) Multicenter collaborative panic disorder severity scale. Am J Psychiat 154: 1571-1575.
40. Siegmund A, Golfels F, Finck C, Halisch A, Räth D, et al. (2011) D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiat Res 45 (8): 1042-1047.
41. Bandelow B (1995) Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharm 10 (2): 73-81.
42. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, et al. (2006) Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiat 63 (3): 298-304. (Pubitemid 43345354)
43. DiNardo PA (1994) Anxiety disorders interview schedule for DSM-IV: lifetime version (ADIS-IV-L). New York: Graywind Publicatons.
44. Turner SM, Beidel DC, Dancu CV, Stanley MA (1989) An empirically derived inventory to measure social fears and anxiety: the Social Phobia and Anxiety Inventory. Psychol Assess 1: 35-40.
45. Liebowitz MR (1987) Social phobia. Mod Probl Pharmacopsychiatry 22: 141-173.
46. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, et al. (2008) A randomized controlled trial of D-Cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiat 63 (6): 544-549.
47. Brown T (1994) Anxiety disorders interview schedule adult version (ADIS-IV). San Antonio (TX): Psychological Corporation/Graywind Publications.
48. Rapee RM, Abbott MJ, Baillie AJ, Gaston JE (2007) Treatment of social phobia through pure self help and therapist-augmented self help. Br J Psychiatry 191: 246-252. (Pubitemid 47435056)
49. Kleine RA, Hendriks G, Kusters WJC, Broekman TG, Minnen A (2012) A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiat 71 (11): 962-968.
50. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, et al. (2012) A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiat Res 46 (9): 1184-1190.
51. Norberg MM, Krystal JH, Tolin DF (2008) A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiat 63 (12): 1118-1126.
52. Bontempo A, Panza KE, Bloch MH (2012) D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J Clin Psychiat 73 (4): 533-537.
53. Ganasen KA, Ipser JC, Stein DJ (2010) Augmentation of cognitive behavioral therapy with pharmacotherapy. Psychiatr Clin N Am 33 (3): 687-699.
54. Hofmann SG, Pollack MH, Otto MW (2006) Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev 12 (3-4): 208-217. (Pubitemid 46047788)
55. Hofmann SG, Sawyer AT, Asnaani A (2012) D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Curr Pharm Des 18: 5659-5662.
56. Popik P, Wrobel M, Nowak G (2000) Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence. Neuropharmacol 39 (12): 2278-2287. (Pubitemid 30642770)
57. Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG (2007) Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr 12 (1): 51-66, 59-61.
58. Boje KM, Wong G, Skolnick P (1993) Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 603 (2): 207-214. (Pubitemid 23069216)
59. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH (1994) Acutebut not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 257 (1-2): 7-12. (Pubitemid 24178543)
60. Santini E, Muller RU, Quirk GJ (2001) Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 21 (22): 9009-9017. (Pubitemid 33054862)
61. Ledgerwood L, Richardson R, Cranney J (2003) Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 117 (2): 341-349. (Pubitemid 36384252)
62. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, et al. (2010) Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with D-cycloserine. Behav Res Ther 48: 675-679.
63. DeSouza DC, Gil R, Morrisey K, Abi-Saab D, White J, et al. (2000) IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 47: 45-62.
64. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, et al. (2002) Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J of Neuropsychoph 5: 301-307. (Pubitemid 35470350)
65. Otto MW, Smits JA, Reese HE (2004) Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry 65 (5): 34-41.
66. Gonçalves R, Lages AC, Rodrigues H, Pedrozo AL, Coutinho ESF, et al. (2011) Potential biomarkers of cognitive behavior-therapy for post-traumatic stress disorder: a systematic review. Rev Psiq Clín 38 (4): 155-160.
67. Javitt DC (2013) Harnessing n-methyl-d-aspartate receptors for new treatment development in psychiatry: positive lessons from negative studies. Am J Psychiatry 170 (7): 699-702.
68. Storch EA, McKay D, Reid JB, Geller DA, Goodman C, et al. (2010) D-cycloserine augmentation of cognitive-behavioral therapy: Directions for pilot research in pediatric obsessive-compulsive disorder. Child Youth Care For 39 (2): 101-112.
69. Byrne SP, Farrell LJ, Rapee RM (2011) Using cognitive enhancers to improve the treatment of anxiety disorders in young people: Examining the potential for D-cycloserine to augment exposure for child anxiety. Clin Psychol 15 (1): 1-9.
70. Smits JAJ, Rosenfield D, Otto MW, Powers MB, Hofmann SG, et al. (2013) D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 73 (11): 1054-1058.
71. Hofmann SG, Wu JQ, Boettcher H (2013) D-cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord 3 (11): 1-10.